Short-course radiation therapy for oropharynx cancer
Official title: Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase III Trial
Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT04178174 · Data updated 2026-11-12
This study is testing a shorter and more targeted radiation treatment for people with HPV-related throat cancer to see if it can reduce side effects while still being effective.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 360 (estimated) |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (London, Ontario and 1 other locations) |
| Status | Recruiting |
| Started | February 23, 2020 |
| Main results expected | December 2028 |
| Study ends | December 2030 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT04178174 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with biopsy-proven HPV-positive squamous cell carcinoma of the oropharynx, staged T1-3, N1 M0.
✕Probably not a fit
Patients with advanced clinical N3 classification or previous head and neck irradiation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial compares the outcomes of a short-course chemoradiation approach using stereotactic boost to the tumor and de-escalated chemoradiation to the neck against the standard 7-week chemoradiation regimen for patients with HPV-associated oropharynx cancer. The study aims to reduce treatment duration and associated toxicities while maintaining efficacy. By utilizing stereotactic ablative radiotherapy (SABR), the trial seeks to deliver precise radiation doses, minimizing exposure to surrounding healthy tissues. The goal is to improve patient quality of life and treatment outcomes in this specific cancer population.
Why it matters
Potential benefit: If successful, this approach could lead to reduced treatment duration and lower toxicity for patients with oropharynx cancer.
How similar studies have gone: Previous studies have shown promising results with similar de-escalation strategies in HPV-positive oropharynx cancer, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Ability to provide written informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx. * Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH) * Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition. * Primary tumor \< 30 cc * Planned for curative chemoradiation * For females of child-bearing age, a negative pregnancy test Exclusion Criteria: * Clinical N3 classification, as per AJCC 8th edition * Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction). * Previous irradiation of the head and neck region * Previous surgery of the HNC region (except for incisional or excisional biopsies) * Pregnancy or breastfeeding * Connective tissue disease * Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy. * Non-Cisplatin concurrent chemotherapy * Prior induction chemotherapy
Where it's running
-
London Health Sciences Center
London, Ontario, Canada Recruiting -
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: David Palma, MD PhD — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Study coordinator: Diane Trudel
- Email: diane.dt.chum@ssss.gouv.qc.ca
- Phone: 514-890-8254
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methotrexate with erlotinib and celecoxib for recurrent or metastatic head and neck cancer in rural Midwest patients
This trial tests whether combining methotrexate, erlotinib, and celecoxib can help adults in the rural Midwest whose head and neck cancer has returned or spread.
-
New blood test to reduce radiation in HPV-related throat cancer treatment
This study is testing a new blood test to see if it can help identify patients with HPV-related throat cancer who might not need radiation after surgery, aiming to reduce side effects while keeping survival rates high.
-
Comparing navigation support to standard care for starting radiation therapy in head and neck cancer patients
This study is testing a new support program to help people with head and neck cancer start their radiation therapy on time compared to the usual care they receive.
-
New surgical procedure for reconstructing the oral cavity and oropharynx in cancer patients
This study is testing a new surgical method using a special tissue flap to see if it can safely help cancer patients who need reconstruction in their mouth and throat areas.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.